Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Villeurbanne – page 163

2 127 clinical trials in Villeurbanne, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villeurbanne at a glance
2 127
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 127 trials in Villeurbanne

Open in trial search

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab, Trastuzumab, and Chemotherapy for Patients with HER2 Positive Advanced Stomach or Gastroesophageal Junction Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia+1

Not recruiting

Study of NMS-03592088 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NMS-03592088
  • Sponsor:Nerviano Medical Sciences S.r.l.

Multiple sclerosis+2

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab, Methylprednisolone, and Diphenhydramine Hydrochloride in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study of Adagrasib Dosing in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Study on Brentuximab Vedotin and Drug Combination for Patients with Peripheral T-cell Lymphoma with Less Than 10% CD30 Expression

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

K-ras gene mutation+3

Not recruiting

Study of JDQ443 and Ribociclib in Combination for Adult Patients with Advanced Solid Tumors with KRAS G12C Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Novartis Pharma AG

Study on RZ358 for Treating Congenital Hyperinsulinism in Patients

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Anti-(Insulin Receptor) Human Monoclonal Antibody
  • Sponsor:Rezolute Inc.

Cystic fibrosis

Not recruiting

Study on the Effects of Inhaled ETD001 for People with Cystic Fibrosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:ETD001A
  • Sponsor:Enterprise Therapeutics Limited

Study of Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Kite Pharma Inc.

Study on the Effectiveness and Safety of Autogene Cevumeran, Atezolizumab, and mFOLFIRINOX in Patients with Resected Pancreatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Genentech Inc.

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Villeurbanne

What the registry says about research in the country

01 Neurodegenerative Diseases

Extensive research focusing on Alzheimer's disease treatments, including multiple studies evaluating novel therapeutic approaches for early-stage patients. Additional investigations examine Parkinson's disease and serotonergic receptor expression.

  • Early Alzheimer's Disease Interventions
  • Parkinson's Disease Mechanisms
  • Cognitive Function Assessment

Studies utilize innovative compounds and treatment strategies to address disease progression and symptoms.

02 Cardiovascular Health

Innovative research targeting heart failure prevention through combination therapy approaches. Studies evaluate new treatment strategies for reducing cardiovascular risks and improving patient outcomes.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Combined Therapeutic Approaches

Focus on preventive strategies and risk reduction in high-risk populations.

03 Oncology Research

Comprehensive studies in various cancer types, including colorectal cancer, breast cancer, and gastric cancer. Research emphasizes personalized treatment approaches and innovative therapeutic strategies.

  • Colorectal Cancer Treatment
  • Breast Cancer Hormone Therapy
  • Gastrointestinal Oncology

Trials incorporate advanced diagnostic methods and targeted therapies.

04 Respiratory Medicine

Studies examining treatments for severe asthma and COPD, evaluating new therapeutic combinations and investigating treatment responses in respiratory conditions.

  • Asthma Management
  • COPD Interventions
  • Respiratory Treatment Optimization

Focus on improving pulmonary outcomes and patient quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.